Microsoft Word - 150202_Acquisition of Own Shares.docx Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of
the Companies Act)
Tokyo, February 2, 2015 - Astellas Pharma Inc. (Tokyo4503, President and CEO: Yoshihiko Hatanaka, hereinafter called "the Company") announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is
applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
1. Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.
2. Contents of acquisition
(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: Up to 15 million shares
(The percentage compared to the total number of shares outstanding: 0.68%)
(3) Aggregate amount of acquisition cost: Up to 30 billion yen
(4) Period of acquisition: From February 3, 2015 to March 17, 2015 (Reference)
The status of treasury shares as of December 31, 2014:
Total number of shares outstanding: 2,208,059,034 shares
Number of treasury shares: 51,764,141 shares

######
For inquiries or additional information
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en

distributed by